Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: The study objective was to investigate whether changes in metabolic phenotype affect the risk of cardiovascular events.
Methods: All 117,589 participants were included in this retrospective cohort study. The metabolic phenotypes of the participants were assessed at two points (the second evaluation was set 2 years after the first evaluation), and the incidence rate of cardiovascular events was observed for 11 years. The main outcome was 3-point major adverse cardiac events (MACE), which comprises cardiovascular death, nonfatal coronary artery disease, and nonfatal stroke incidence.
Results: Of the participants, 2748 (2.3%) cases of 3-point MACE were identified during follow-up. The stable metabolically healthy obesity group had a higher risk of 3-point MACE than those with stable metabolically healthy nonobesity (MHNO). Additionally, the change from metabolically healthy obesity to MHNO for 2 years decreased the risk of 3-point MACE (hazard ratio [HR], 1.12: 95% CI: 0.84-1.47) to the same level as stable MHNO. However, the change from metabolically abnormal nonobesity and metabolically abnormal obesity to MHNO for 2 years maintained a higher risk of 3-point MACE (HR, 1.66 [95% CI: 1.36-2.01]; HR, 1.91 [95% CI: 1.22-2.81]) than those with stable MHNO.
Conclusions: Change in metabolic phenotype is associated with incident 3-point MACE.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/oby.23999 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of SGLT-2i and GLP-1RA on cardiovascular and renal outcomes in elderly patients with T2DM: a single-center retrospective cohort study.
Int Urol Nephrol
September 2025
Department of Pharmacy, The Affiliated Xuzhou Children's Hospital of Xuzhou Medical University, No. 18, Sudi North Road, Quanshan District, Xuzhou City, 221000, China.
Purpose: While SGLT-2i and GLP-1RA show cardiorenal benefits, their comparative efficacy in elderly type 2 diabetes mellitus (T2DM) patients remains uncertain. This study aimed to compare SGLT-2i and GLP-1RA on cardiovascular and renal outcomes in elderly T2DM patients.
Methods: This retrospective study analyzed 1,015 propensity score-matched elderly T2DM patients (SGLT-2i group: n = 583; GLP-1RA group: n = 432).
Comparative cardiovascular outcomes and safety of hypoglycemic drug classes in patients with type 2 diabetes and hypertension: a multicenter cohort analysis.
Cardiovasc Diabetol
August 2025
Department of Medical Informatics, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, 211166, Jiangsu, China.
Background: Patients with type 2 diabetes (T2D) and hypertension are at increased risk of adverse cardiovascular (CV) events. However, real-world evidence comparing the CV effectiveness and safety of major hypoglycemic drug classes remains limited in this population. This multicenter pooled analysis aims to directly compare the CV outcomes and safety profiles of these key agents in patients with T2D and hypertension.
View Article and Find Full Text PDFEfficacy of GLP-1 receptor agonists among older adults: a meta-analysis of cardio-kidney outcome trials.
Arch Gerontol Geriatr
November 2025
Baylor College of Medicine, Temple, TX, USA; Baylor Scott and White Heart Hospital, Plano, TX, USA; Baylor Scott and White Research Institute, Baylor Scott and White Health, Dallas, TX, USA.
Background: Older adults face high cardiovascular (CV) and kidney risk but may be underrepresented in randomized controlled trials (RCTs). While GLP-1RAs have been shown to provide CV and kidney benefits, estimates for efficacy and safety endpoints among older adults remain less certain. This meta-analysis assesses their impact on CV and kidney outcomes.
View Article and Find Full Text PDFEligibility for icosapent ethyl 1-3 months after acute coronary syndrome and the risk for myocardial re-infarction: Data from the CALLINICUS-Hellas Registry.
Int J Cardiol
December 2025
1st Department of Cardiology, Medical School, National and Kapodistrian, University of Athens, Hippokration Hospital, Athens, Greece.
Icosapent ethyl (IPE) has been shown to reduce adverse cardiovascular (CV) outcomes in high or very high-risk patients on statins with triglyceride (TG) levels between 135 and 499 mg/dL METHODS: The CALLINICUS-Hellas registry is an ongoing, prospective, multicenter study evaluating lipid profiles, adherence to lipid-lowering therapies, and prognosis in acute coronary syndrome (ACS) patients. This analysis included patients with lipids assessed 4-12 weeks post-ACS who were divided into two groups: Those eligible for IPE administration according to the 2019 ESC/EAS guidelines for the Management of Dyslipidaemias and those not eligible. Cardiometabolic profile at discharge and the incidence of 3-point major adverse CV events [3P-MACE; non-fatal myocardial infarction (MI), non-fatal stroke, cardiac death] within 12 months were compared between groups RESULTS: A total of 1254 patients had their lipid profile evaluated 4-12 weeks post-discharge and the vast majority (97.
View Article and Find Full Text PDFBackground: There are few data verifying the utility of the CHADS-PARC score in comparison with the CHADS score for estimating net adverse clinical events (NACE) in chronic coronary syndrome (CCS) patients without atrial fibrillation (AF) in real-world settings.
Methods: We performed analysis for a total of 3985 CCS patients without AF who underwent percutaneous coronary intervention (PCI) between April 2013 and March 2019 for whom information was obtained from the CLIDAS (Clinical Deep Data Accumulation System)-PCI database. The primary endpoint was NACE defined as the composite of 3-point major adverse cardiovascular events (3P-MACE) (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) and GUSTO moderate/severe bleeding events.